ANIX Insider Trading
Insider Ownership Percentage: 25.30%
Insider Buying (Last 12 Months): $412,198.89
Insider Selling (Last 12 Months): $0.00
Anixa Biosciences Insider Trading History Chart
This chart shows the insider buying and selling history at Anixa Biosciences by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Anixa Biosciences Share Price & Price History
Current Price: $2.97
Price Change: ▼ Price Decrease of -0.11 (-3.57%)
As of 03/28/2025 05:00 PM ET
Anixa Biosciences Insider Trading History
Anixa Biosciences Institutional Trading History
Data available starting January 2016
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Read More on Anixa Biosciences
Volume
81,233 shs
Average Volume
97,441 shs
Market Capitalization
$95.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.86
Who are the company insiders with the largest holdings of Anixa Biosciences?
Who are the major institutional investors of Anixa Biosciences?
Which major investors are selling Anixa Biosciences stock?
During the last quarter, ANIX stock was sold by these institutional investors:
- Mission Wealth Management LP
- International Assets Investment Management LLC
- Long Focus Capital Management LLC
- Bank of America Corp DE
- Northern Trust Corp
Which major investors are buying Anixa Biosciences stock?
In the previous quarter, ANIX stock was acquired by institutional investors including:
- Focus Partners Wealth
- Jane Street Group LLC
- Prosperity Wealth Management Inc.
- LPL Financial LLC
- Millennium Management LLC
- Citadel Advisors LLC
- Renaissance Technologies LLC
In the last year, these company insiders have bought Anixa Biosciences stock:
- Lewis H Titterton Jr (Director)
- Amit Kumar (CEO)
- Arnold M Baskies (Director)
- Michael Catelani (CFO)
Learn More investors buying Anixa Biosciences stock.